https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg001997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-66https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-661997-04-01 00:00:002020-06-23 09:47:26Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
